The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Damme, J.
Right arrow Articles by Billiau, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Damme, J.
Right arrow Articles by Billiau, A.

The Journal of Immunology, Vol 139, Issue 6 1867-1872, Copyright © 1987 by American Association of Immunologists


ARTICLES

The role of interferon-beta 1 and the 26-kDa protein (interferon-beta 2) as mediators of the antiviral effect of interleukin 1 and tumor necrosis factor

J Van Damme, M De Ley, J Van Snick, CA Dinarello and A Billiau

This study confirms our earlier finding that human interleukin (IL)-1 beta exerts an antiviral effect on diploid fibroblasts and on MG-63 osteosarcoma cells. It also extends the observation in that a similar effect was noted on aged but not freshly trypsinized HEp-2 cells, and that not only IL-1 beta but also IL-1 alpha and tumor necrosis factor (TNF)-alpha exerted similar antiviral effects on cells. The antiviral effects of these cytokines were neutralized by addition to the assay system of an antibody that was specific for interferon (IFN)-beta 1, indicating that IFN-beta 1 or a structurally or functionally related substance is involved in the antiviral activity observed. Both IL-1 and TNF were able to induce production of the 26-kDa protein, also known as IFN-beta 2, hybridoma/plasmacytoma growth factor (HPGF) or B-cell stimulatory factor-2 (BSF-2) and previously proposed as an alternative to IFN-beta 1 for mediating the antiviral effect of TNF. However, no good correlation was found between the antiviral effects of TNF and its potential to induce production of the 26-kDa protein. Furthermore, the anti-IFN-beta 1 serum which neutralized the antiviral activity of IL-1 and TNF did not cross-react with the 26-kDa protein. Conversely, the antiviral effect of IL-1 and TNF was only weakly neutralized by an antibody that did react with the 26-kDa protein and showed low cross- reactivity with IFN-beta 1. These observations, together with the low specific activity of the 26-kDa protein as an antiviral agent (less than 10(5) U/mg protein) provide strong arguments against this protein and in favor of IFN-beta 1 (or still another IFN-beta 1-related molecule) as the ultimate mediator of the antiviral effect of IL-1 and TNF.


This article has been cited by other articles:


Home page
J. Immunol.Home page
G. Chan, E. R. Bivins-Smith, M. S. Smith, P. M. Smith, and A. D. Yurochko
Transcriptome Analysis Reveals Human Cytomegalovirus Reprograms Monocyte Differentiation toward an M1 Macrophage
J. Immunol., July 1, 2008; 181(1): 698 - 711.
[Abstract] [Full Text] [PDF]


Home page
J Hum LactHome page
E. P. Hines, J. L. Rayner, R. Barbee, R. A. Moreland, A. Valcour, J. E. Schmid, and S. E. Fenton
Assays for Endogenous Components of Human Milk: Comparison of Fresh and Frozen Samples and Corresponding Analytes in Serum
J Hum Lact, May 1, 2007; 23(2): 144 - 156.
[Abstract] [PDF]


Home page
J. Leukoc. Biol.Home page
I. Nelissen, I. Ronsse, J. Van Damme, and G. Opdenakker
Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta
J. Leukoc. Biol., January 1, 2002; 71(1): 89 - 98.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
I. P. Ceravolo, A. C. L. Chaves, C. A. Bonjardim, D. Sibley, A. J. Romanha, and R. T. Gazzinelli
Replication of Toxoplasma gondii, but Not Trypanosoma cruzi, Is Regulated in Human Fibroblasts Activated with Gamma Interferon: Requirement of a Functional JAK/STAT Pathway
Infect. Immun., May 1, 1999; 67(5): 2233 - 2240.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1987 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1987 by The American Association of Immunologists, Inc. All rights reserved.